Abstract

Type 2 diabetes mellitus (DM) is one of the most common noncommunicable diseases on the globe. If at present the number of patients with diabetes in the world is 347 million people, then by 2025, according to scientists, this figure will reach at least 592 million, of which 90% will be in diabetes. Global trends in the incidence of type 2 diabetes are also observed in Uzbekistan. The total number of patients with diabetes in Uzbekistan amounted to 230610 (706.24 per 100 thousand people), of which type 1 diabetes – 18349 (56.2 per 100 thousand people), type 2 diabetes – 212261 (650,0 per 100 thousand people). As a percentage, patients with type 1 diabetes of the total number of patients with diabetes is 8.0%, patients with type 2 diabetes are 92.0%. Maintaining a constantly normal or near normal concentration of glucose in the blood slows down the onset and progression of late complications of type 2 diabetes. In the absence of achieving the target glycemic values against the background of the use of a rational combination of oral hypoglycemic drugs, it is shown that baseline action is added to insulin treatment to suppress liver gluconeogenesis and normalize fasting glucose. The combination of sulfonylurea derivatives (PSM) and basal insulin has been well studied and has proven. In addition, the combined use of metformin and insulin was widely used in the treatment of patients with type 2 diabetes mellitus (T2DM), however, at present there is no evidence base in favor of their joint appointment.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call